PML抗体;PML Antibody—艾普蒂

+ +

•  

   

     Lane 1: HeLa lysate ;  Lane 2: PML immunoprecipitated from HeLa lysate by P15673 ;  Lane 3: The same as Lane 2 but use IgG isotype control antibody ;Result: P15673 can immunoprecipitate PML;    

  
  

PML (Promyelocytic Leukemia) antibodies are autoantibodies targeting the PML protein, a key component of nuclear structures known as PML nuclear bodies (PML-NBs). These dynamic organelles play crucial roles in diverse cellular processes, including transcriptional regulation, apoptosis, DNA repair, and antiviral responses. The PML protein itself is involved in tumor suppression and genome stability, with its gene frequently disrupted in acute promyelocytic leukemia (APL) due to chromosomal translocations forming PML-RARα fusion proteins.

In autoimmune contexts, PML antibodies are primarily associated with specific subsets of autoimmune diseases, particularly in patients with dermatomyositis (DM) or systemic sclerosis (scleroderma). They are often detected alongside other myositis-specific autoantibodies, such as anti-SAE or anti-MDA5. The presence of PML antibodies may correlate with distinct clinical phenotypes, though their exact pathogenic role remains unclear. Hypotheses suggest that PML protein overexpression or aberrant immune activation in certain conditions could trigger autoantibody production.

Clinically, PML antibodies serve as diagnostic biomarkers rather than direct drivers of tissue damage. Their detection aids in subclassifying autoimmune disorders and guiding prognosis. Research continues to explore their potential role in disease mechanisms, particularly in modulating interferon signaling pathways, which are hyperactive in many autoimmune conditions. Notably, PML antibodies are distinct from the JC virus-induced PML (progressive multifocal leukoencephalopathy), a rare neurological complication in immunocompromised individuals.